Alnylam Pharmaceuticals, Inc. (ALNY) vs Quest Diagnostics Incorporated (DGX)
A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and Quest Diagnostics Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 30, 2026. Differences are shown without an overall score or investment verdict.
ALNY
Alnylam Pharmaceuticals, Inc.
$205.48HealthcareDelayed quote: Jul 30, 2026, 4:00 PM EDT
DGX
Quest Diagnostics Incorporated
$234.30HealthcareDelayed quote: Jul 30, 2026, 4:00 PM EDT
Total return — ALNY vs DGX
growth of $100 · dividends reinvested · last 22yALNY +4698.8%DGX +674.1%ALNY compounded faster
Log scale — wide-divergence pair
ALNY DGX
ALNY vs DGX: by the numbers
- •ALNY is the larger company ($27.43B vs $25.86B market cap).
- •DGX trades at the lower trailing earnings multiple (24.97 vs 34.71 P/E), one valuation lens rather than an overall verdict.
- •ALNY converts more revenue to profit (16.82% vs 12.02% net margin).
- •ALNY grew revenue faster over the past five years (47.53% vs 0.89% CAGR).
- •DGX pays a dividend (1.41% yield), while ALNY has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | ALNY | DGX |
|---|---|---|
| P/E ratio | 34.71 | 24.97 |
| Forward P/E | 27.69 | 21.06 |
| P/S ratio | 5.91 | 2.28 |
| P/B ratio | 20.98 | 3.51 |
| PEG ratio | N/A | 1.43 |
| EV / EBITDA | 27.23 | 16.70 |
| FCF yield | 2.79% | 5.12% |
Profitability
| Metric | ALNY | DGX |
|---|---|---|
| Gross margin | 81.77% | 33.15% |
| Operating margin | 20.81% | 14.14% |
| Net margin | 16.82% | 12.02% |
| ROE | 59.67% | 18.49% |
| ROIC | 13.74% | 8.43% |
Dividends
| Metric | ALNY | DGX |
|---|---|---|
| Dividend yield | N/A | 1.41% |
| Payout ratio | N/A | 37.43% |
Growth (annualized)
| Metric | ALNY | DGX |
|---|---|---|
| Revenue CAGR (5Y) | 47.53% | 0.89% |
| EPS CAGR (5Y) | N/A | -3.65% |
| FCF CAGR (5Y) | 15.55% | -9.08% |
| Total return CAGR (5Y) | 2.80% | 12.92% |
Frequently asked
- Which has the lower trailing P/E, ALNY or DGX?
- DGX has the lower trailing P/E: ALNY trades at 34.71 and DGX at 24.97. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, ALNY or DGX?
- Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus DGX at 0.89%.
- Does ALNY or DGX pay a bigger dividend?
- DGX pays a dividend (1.41% yield), while ALNY has no payments in the available dividend history.
- Is ALNY or DGX more profitable?
- ALNY runs the higher net margin — ALNY at 16.82% versus DGX at 12.02%.
- How have ALNY and DGX total returns compared?
- Over the past 10 years, ALNY delivered 11.68% and DGX delivered 12.74% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Alnylam Pharmaceuticals P/E ratioQuest Diagnostics P/E ratioAlnylam Pharmaceuticals dividend yieldQuest Diagnostics dividend yieldAlnylam Pharmaceuticals ROEQuest Diagnostics ROEAlnylam Pharmaceuticals operating marginQuest Diagnostics operating marginAlnylam Pharmaceuticals revenue growthQuest Diagnostics revenue growthAlnylam Pharmaceuticals free cash flowQuest Diagnostics free cash flow
Alnylam Pharmaceuticals & Quest Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 30, 2026.